/ 机构调研pro小程序 步长制药分析师会议 调研日期：2025年09月26日 调研行业：中药 参与调研的机构：投资者等 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 | | ...

Core Insights - The Chinese medicine industry is undergoing a significant transformation, with the centralized procurement of traditional Chinese medicine (TCM) products acting as a catalyst for change, prompting major companies to integrate their supply chains to adapt to market pressures and regulatory shifts [1][2] Group 1: Industry Trends - The centralized procurement led by Hubei allows for a 60% price component and 40% based on technical factors, emphasizing the importance of quality and innovation in TCM [2] - The State Council's 2025 report highlights the need for high-quality development in the TCM sector, indicating a shift from resource-driven competition to quality-driven value [2][12] - The TCM industry has experienced a volatile price environment, with the index rising from over 2000 points in 2019 to a peak of 3600 points, followed by a decline due to oversupply and market speculation [3] Group 2: Company Performance - Yunnan Baiyao reported a revenue of 21.257 billion yuan in the first half of 2025, a year-on-year increase of 3.92%, with net profit reaching 3.633 billion yuan, up 13.93% [4] - In 2024, Yunnan Baiyao achieved a revenue of 40.033 billion yuan, a 2.36% increase, and a net profit of 4.523 billion yuan, reflecting a 20.18% growth [4] Group 3: Supply Chain Integration - Yunnan Baiyao's strategy involves integrating the entire supply chain, from seed selection to processing, ensuring quality and stability in raw materials [5][6] - The company has developed a model that promotes collaboration with local farmers, allowing them to sell fresh herbs directly to Yunnan Baiyao, thus enhancing quality and income for farmers [10] Group 4: Digital Transformation - Yunnan Baiyao is leveraging digital platforms to enhance supply chain transparency and efficiency, enabling full-process collaboration and traceability in TCM production [8] - The company has introduced a data product for tracing Yunnan's unique TCM materials, promoting industry-wide data sharing and collaboration [8] Group 5: Future Outlook - Yunnan Baiyao aims to expand its market presence internationally, utilizing its geographical advantages and establishing a new international trading center for medicinal materials [11] - The company has initiated a 10 billion yuan industry fund to support the development of the TCM sector, indicating a commitment to long-term growth and innovation [11][12]

Core Viewpoint - The company emphasizes its commitment to innovation and product efficacy enhancement across the entire industry chain, focusing on traditional and modern practices in its operations [1] Group 1: Product Innovation - The company has developed a unique wall-breaking technology that removes the shell of Ganoderma lucidum spore powder, resulting in over tenfold increases in the content of effective components [1] - The absorption rates of different effective components have improved by 4 to 50 times due to this new technology [1] Group 2: Research and Development - The company is conducting research on the combination of wall-broken Ganoderma lucidum spore powder with anti-tumor drugs, with some results already published in academic papers [1]

Core Viewpoint - Tongrentang has received a traditional medicine registration license from the Ministry of Health of Cambodia, allowing the sale of "Tongrentang An Gong Niu Huang Wan" in Cambodia until September 11, 2028 [1] Group 1 - The license was issued to Tongrentang's subsidiary, Beijing Tongrentang Guoyao Co., Ltd [1] - The approval marks a significant step for the company in expanding its international market presence [1]

Core Viewpoint - Hansen Pharmaceutical (002412) is currently in the process of scaling up the production technology for its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot study phase [1] Group 1 - The company is actively engaged in product research and development [1] - Cangrong Granules is a new drug derived from traditional Chinese medicine [1] - The product is currently undergoing process pilot testing [1]

Core Viewpoint - Tong Ren Tang (600085.SH) has received a Traditional Medicine Registration License from the Ministry of Health of Cambodia, allowing its product "Tong Ren Tang An Gong Niu Huang Wan" to be sold in Cambodia [1] Group 1: Regulatory Approvals - The subsidiary Beijing Tong Ren Tang Guo Yao Co., Ltd. has obtained the Traditional Medicine Registration License, which follows the previously granted import license for the same product [1] - This license enables the distribution of Tong Ren Tang An Gong Niu Huang Wan in Cambodia, enhancing the product's market presence [1] Group 2: Market Expansion - The acquisition of the registration license is expected to enrich the distribution channels for key products of Tong Ren Tang Guo Yao, facilitating market expansion [1] - The impact of this license on the company's production operations and overall performance is not anticipated to be significant at this time [1]

Core Insights - Tong Ren Tang Technology (01666.HK) announced that its subsidiary, Tong Ren Tang Guo Yao, has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1][2] Group 1 - The drug "Tong Ren Tang An Gong Niu Huang Wan" is now authorized for sale in Cambodia, which will enhance the distribution channels for the company's key products and support market expansion [1][2] - The registration number for the license is CAM N0004IT-25, and it is valid until September 11, 2028 [2] - The acquisition of this license is not expected to have a significant impact on the company's production operations and performance in the short term [2] Group 2 - The sales of the drug may be influenced by changes in Cambodia's policy environment, exchange rate fluctuations, and market competition [2][3]

Core Viewpoint - Tong Ren Tang (600085.SH) has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing its subsidiary Beijing Tong Ren Tang Guo Yao Co., Ltd. to sell "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1] Group 1 - The approval from the Cambodian authorities marks a significant step for the company in expanding its international market presence [1] - The product "Tong Ren Tang An Gong Niu Huang Wan" is a traditional Chinese medicine, indicating the company's commitment to promoting traditional medicine abroad [1]

Core Viewpoint - Beijing Tong Ren Tang Co., Ltd. announced that its subsidiary, Beijing Tong Ren Tang Guo Yao Co., Ltd., received a Traditional Medicine Registration License from the Cambodian Ministry of Health, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia, which is valid until 2028 [1] Group 1 - The license number for the registration is CAMN00041T - 25, and it follows the prior import license obtained for the product [1] - This registration is expected to enhance distribution channels and expand market reach, although it will not have a significant impact on the company's production operations and performance in the short term [1] - The sales of the medicine are subject to influences from policies, exchange rates, and competition, indicating potential risks for investors [1]

Core Viewpoint - Tong Ren Tang's subsidiary, Tong Ren Tang Guo Yao, has received a Traditional Medicine Registration License from the Cambodian Ministry of Health, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1] Company Summary - The approval from the Cambodian authorities marks a significant step for Tong Ren Tang Guo Yao in expanding its market presence in Southeast Asia [1] - The product "An Gong Niu Huang Wan" is a traditional Chinese medicine, which may appeal to both local consumers and tourists in Cambodia [1] Industry Summary - The traditional medicine market in Cambodia is expected to grow, driven by increasing consumer interest in herbal and alternative remedies [1] - Regulatory approvals like the one received by Tong Ren Tang Guo Yao are crucial for companies looking to enter or expand in the Southeast Asian pharmaceutical market [1]